Skip to main content
Erschienen in: Pediatric Nephrology 2/2013

01.02.2013 | Review

The contribution of systematic reviews to the practice of pediatric nephrology

verfasst von: Elisabeth Hodson, Jonathan C. Craig

Erschienen in: Pediatric Nephrology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

The key to accurate decision-making is to use the best available evidence. Systematic reviews aim to identify and combine evidence using systematic methods to minimize bias to provide reliable data for patient care. While systematic reviews can address different clinical questions, the methodology is most developed for systematic reviews of randomized controlled trials. Such systematic reviews include all available trial evidence, enhance the precision of the estimates of treatment effects, and identify where evidence is lacking or where sufficient evidence is already available. However the term “systematic review“ does not guarantee that a review covers all the available data, that the validity of included studies has been appropriately assessed, or that data have been combined appropriately in meta-analyses. Biases in systematic review include those related to identifying data (publication bias, language bias, selective reporting of outcomes) and those due to the design and conduct of trials (selection bias, performance bias, detection bias, attrition bias). Thus, readers should read a systematic review carefully before accepting its results and conclusions. This review examines the information that can be provided by systematic reviews of randomized controlled trials together with the biases that can potentially jeopardize the results and conclusions.
Literatur
1.
Zurück zum Zitat Davies K (2009) Quantifying the information needs of doctors in the UK using clinical librarians. Health Info Libr J 26:289–297PubMedCrossRef Davies K (2009) Quantifying the information needs of doctors in the UK using clinical librarians. Health Info Libr J 26:289–297PubMedCrossRef
2.
Zurück zum Zitat Bastian H, Glasziou P, Chalmers I (2010) Seventy-five trials and eleven systematic reviews a day: how will we ever keep up? PLoS Med 7:e1000326PubMedCrossRef Bastian H, Glasziou P, Chalmers I (2010) Seventy-five trials and eleven systematic reviews a day: how will we ever keep up? PLoS Med 7:e1000326PubMedCrossRef
3.
Zurück zum Zitat Schuster MA, McGlynn EA, Brook RH (1998) How good is the quality of health care in the United States? Milbank Q 76:517–563PubMedCrossRef Schuster MA, McGlynn EA, Brook RH (1998) How good is the quality of health care in the United States? Milbank Q 76:517–563PubMedCrossRef
4.
Zurück zum Zitat Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC (2004) Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 77:166–176PubMedCrossRef Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC (2004) Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 77:166–176PubMedCrossRef
5.
Zurück zum Zitat US Renal Data System. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD., pp Chapter 7, Figure 7.34, Volume 2 US Renal Data System. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD., pp Chapter 7, Figure 7.34, Volume 2
6.
Zurück zum Zitat US Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD., pp Chapter 7, Figure 7.29, Volume 2 US Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD., pp Chapter 7, Figure 7.29, Volume 2
7.
Zurück zum Zitat US Renal Data System. USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD., pp Chapter 7, Figure 7.28, Volume 2 US Renal Data System. USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD., pp Chapter 7, Figure 7.28, Volume 2
8.
Zurück zum Zitat Campbell S, McDonald S, Webster AC, Excell L (2009) ANZDATA Registry Report Australia and New Zealand Dialysis and Transplant Registry. Adelaide, South Australia, pp 8–1 to 8–25 Campbell S, McDonald S, Webster AC, Excell L (2009) ANZDATA Registry Report Australia and New Zealand Dialysis and Transplant Registry. Adelaide, South Australia, pp 8–1 to 8–25
9.
Zurück zum Zitat Clayton P, Excell L, Campbell S, Chadban S (2010) ANZDATA Registry Report. Adelaide, South Australia.: Australia and New Zealand Dialysis and Transplant Registry, pp 8–1 to 8–31. Clayton P, Excell L, Campbell S, Chadban S (2010) ANZDATA Registry Report. Adelaide, South Australia.: Australia and New Zealand Dialysis and Transplant Registry, pp 8–1 to 8–31.
10.
Zurück zum Zitat Chalmers I, Glasziou P (2009) Avoidable waste in the production and reporting of research evidence. Lancet 374:86–89PubMedCrossRef Chalmers I, Glasziou P (2009) Avoidable waste in the production and reporting of research evidence. Lancet 374:86–89PubMedCrossRef
11.
Zurück zum Zitat Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K (2009) Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Data Syst Rev Jan 21:MR000006 Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K (2009) Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Data Syst Rev Jan 21:MR000006
12.
Zurück zum Zitat Mohan S, Radhakrishnan J (2010) Do meta-analyses in nephrology change the way we treat patients? Kidney Int 78:1080–1087PubMedCrossRef Mohan S, Radhakrishnan J (2010) Do meta-analyses in nephrology change the way we treat patients? Kidney Int 78:1080–1087PubMedCrossRef
13.
Zurück zum Zitat Moher D, Tetzlaff J, Tricco AC, Sampson M, Altman DG (2007) Epidemiology and reporting characteristics of systematic reviews. PLoS Med 4:e78PubMedCrossRef Moher D, Tetzlaff J, Tricco AC, Sampson M, Altman DG (2007) Epidemiology and reporting characteristics of systematic reviews. PLoS Med 4:e78PubMedCrossRef
14.
Zurück zum Zitat Glass GV (1976) Primary, secondary and meta-analysis of research. Educ Res 5:3–8 Glass GV (1976) Primary, secondary and meta-analysis of research. Educ Res 5:3–8
15.
Zurück zum Zitat Higgins JPT, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration Higgins JPT, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration
16.
Zurück zum Zitat Webster AC, Cross NB, Mitchell R, Craig JC (2010) How to get the most from the medical literature: searching the medical literature effectively. Nephrology 15:12–19PubMedCrossRef Webster AC, Cross NB, Mitchell R, Craig JC (2010) How to get the most from the medical literature: searching the medical literature effectively. Nephrology 15:12–19PubMedCrossRef
17.
Zurück zum Zitat Henderson LK, Craig JC, Willis NS, Tovey D, Webster AC (2010) How to write a Cochrane systematic review. Nephrology 15:617–624PubMedCrossRef Henderson LK, Craig JC, Willis NS, Tovey D, Webster AC (2010) How to write a Cochrane systematic review. Nephrology 15:617–624PubMedCrossRef
18.
Zurück zum Zitat Webster AC, Ruster LP, McGee R, Matheson SL, Higgins GY, Willis NS, Chapman JR, Craig JC (2010) Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Data Syst Rev Jan 20:CD003897 Webster AC, Ruster LP, McGee R, Matheson SL, Higgins GY, Willis NS, Chapman JR, Craig JC (2010) Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Data Syst Rev Jan 20:CD003897
19.
Zurück zum Zitat Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, Robinson CA (1997) Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 350:1729–1733PubMedCrossRef Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S, Robinson CA (1997) Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected]. Lancet 350:1729–1733PubMedCrossRef
20.
Zurück zum Zitat Hodson EM, Craig JC, Strippoli GFM, Webster AC (2008) Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Data Syst Rev Jan 2:CD003774 Hodson EM, Craig JC, Strippoli GFM, Webster AC (2008) Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Data Syst Rev Jan 2:CD003774
21.
Zurück zum Zitat Hodson EM, Willis NS, Craig JC (2008) Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Data Syst Rev Jan 23:CD002290 Hodson EM, Willis NS, Craig JC (2008) Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Data Syst Rev Jan 23:CD002290
22.
Zurück zum Zitat Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364:2021–2029PubMedCrossRef Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364:2021–2029PubMedCrossRef
23.
Zurück zum Zitat Phrommintikul A, Haas SJ, Elsik M, Krum H (2007) Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369:381–388PubMedCrossRef Phrommintikul A, Haas SJ, Elsik M, Krum H (2007) Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369:381–388PubMedCrossRef
24.
Zurück zum Zitat Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R: for the TREAT Investigators (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019–2032PubMedCrossRef Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R: for the TREAT Investigators (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019–2032PubMedCrossRef
25.
Zurück zum Zitat Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, Pellegrini F, Ravani P, Jardine M, Perkovic V, Graziano G, McGee R, Nicolucci A, Tognoni G, Strippoli GFM (2010) Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 153:23–33PubMed Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, Pellegrini F, Ravani P, Jardine M, Perkovic V, Graziano G, McGee R, Nicolucci A, Tognoni G, Strippoli GFM (2010) Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 153:23–33PubMed
26.
Zurück zum Zitat Hodson EM, Craig JC (2010) How to apply results from randomized trials and systematic reviews to individual patient care. Nephrology 15:277–280PubMedCrossRef Hodson EM, Craig JC (2010) How to apply results from randomized trials and systematic reviews to individual patient care. Nephrology 15:277–280PubMedCrossRef
27.
Zurück zum Zitat Flynn JT, Kaiser BA, Long SS, Schulman SL, Deforest A, Polinsky MS, Baluarte HJ (1997) Intravenous immunoglobulin prophylaxis of cytomegalovirus infection in pediatric renal transplant recipients. Am J Nephrol 17:146–152PubMedCrossRef Flynn JT, Kaiser BA, Long SS, Schulman SL, Deforest A, Polinsky MS, Baluarte HJ (1997) Intravenous immunoglobulin prophylaxis of cytomegalovirus infection in pediatric renal transplant recipients. Am J Nephrol 17:146–152PubMedCrossRef
28.
Zurück zum Zitat Camacho-Gonzalez AF, Gutman J, Hymes LC, Leong T, Hilinski JA (2011) 24 weeks of valganciclovir prophylaxis in children after renal transplantation: a 4-year experience. Transplantation 91:245–250PubMedCrossRef Camacho-Gonzalez AF, Gutman J, Hymes LC, Leong T, Hilinski JA (2011) 24 weeks of valganciclovir prophylaxis in children after renal transplantation: a 4-year experience. Transplantation 91:245–250PubMedCrossRef
29.
Zurück zum Zitat Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 354:1896–1900PubMedCrossRef Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 354:1896–1900PubMedCrossRef
30.
Zurück zum Zitat Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 6:e1000097PubMedCrossRef Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 6:e1000097PubMedCrossRef
31.
Zurück zum Zitat Delaney A, Bagshaw SM, Ferland A, Manns B, Laupland KB, Doig CJ (2005) A systematic evaluation of the quality of meta-analyses in the critical care literature. Crit Care 9:R575–582PubMedCrossRef Delaney A, Bagshaw SM, Ferland A, Manns B, Laupland KB, Doig CJ (2005) A systematic evaluation of the quality of meta-analyses in the critical care literature. Crit Care 9:R575–582PubMedCrossRef
32.
Zurück zum Zitat Palmer SC, Navaneethan SD, Strippoli GFM (2010) How to read a nephrology systematic review. Nephrology 15:158–164PubMedCrossRef Palmer SC, Navaneethan SD, Strippoli GFM (2010) How to read a nephrology systematic review. Nephrology 15:158–164PubMedCrossRef
33.
Zurück zum Zitat Scherer RW, Langenberg P, von Elm E (2007) Full publication of results initially presented in abstracts. Cochrane Data Syst Rev Apr 18:MR000005 Scherer RW, Langenberg P, von Elm E (2007) Full publication of results initially presented in abstracts. Cochrane Data Syst Rev Apr 18:MR000005
34.
Zurück zum Zitat Tetzlaff J, Moher D, Pham B, Altman DG (2006) Survey of views on including grey literature in systematic reviews. 14th Cochrane Colloquium, Dublin, Ireland Tetzlaff J, Moher D, Pham B, Altman DG (2006) Survey of views on including grey literature in systematic reviews. 14th Cochrane Colloquium, Dublin, Ireland
35.
Zurück zum Zitat Hopewell S, McDonald S, Clarke M, Egger M (2007) Grey literature in meta-analyses of randomized trials of health care interventions. Cochrane Data Syst Rev Apr 18:MR000010 Hopewell S, McDonald S, Clarke M, Egger M (2007) Grey literature in meta-analyses of randomized trials of health care interventions. Cochrane Data Syst Rev Apr 18:MR000010
36.
Zurück zum Zitat Dwan K, Altman DG, Cresswell L, Blundell M, Gamble CL, Williamson PR (2011) Comparison of protocols and registry entries to published reports for randomised controlled trials. Cochrane Data Syst Rev Jan 19:MR000031 Dwan K, Altman DG, Cresswell L, Blundell M, Gamble CL, Williamson PR (2011) Comparison of protocols and registry entries to published reports for randomised controlled trials. Cochrane Data Syst Rev Jan 19:MR000031
37.
Zurück zum Zitat Schulz KF, Chalmers I, Hayes RJ, Altman DG (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273:408–412PubMedCrossRef Schulz KF, Chalmers I, Hayes RJ, Altman DG (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273:408–412PubMedCrossRef
38.
Zurück zum Zitat Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP (1998) Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352:609–613PubMedCrossRef Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP (1998) Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352:609–613PubMedCrossRef
39.
Zurück zum Zitat Egger M, Dickersin K, Davey-Smith G (2001) Problems and limitations in conducting systematic reviews. In: Egger M, Davey-Smith G, Altman DG (eds) Systematic reviews in health care: Meta-analysis in context. BMJ Publishing Group, LondonCrossRef Egger M, Dickersin K, Davey-Smith G (2001) Problems and limitations in conducting systematic reviews. In: Egger M, Davey-Smith G, Altman DG (eds) Systematic reviews in health care: Meta-analysis in context. BMJ Publishing Group, LondonCrossRef
40.
Zurück zum Zitat Hodson EM, Barclay PG, Craig JC, Jones C, Kable K, Strippoli GFM, Vimalachandra D, Webster AC (2005) Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Data Syst Rev Oct 19:CD003774 Hodson EM, Barclay PG, Craig JC, Jones C, Kable K, Strippoli GFM, Vimalachandra D, Webster AC (2005) Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Data Syst Rev Oct 19:CD003774
Metadaten
Titel
The contribution of systematic reviews to the practice of pediatric nephrology
verfasst von
Elisabeth Hodson
Jonathan C. Craig
Publikationsdatum
01.02.2013
Verlag
Springer-Verlag
Erschienen in
Pediatric Nephrology / Ausgabe 2/2013
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-012-2155-3

Weitere Artikel der Ausgabe 2/2013

Pediatric Nephrology 2/2013 Zur Ausgabe

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

23.04.2024 Typ-1-Diabetes Nachrichten

Wenn Kinder an Werktagen zum Arzt gehen, werden neu auftretender Typ-1-Diabetes und diabetische Ketoazidosen häufiger erkannt als bei Arztbesuchen an Wochenenden oder Feiertagen.

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

22.04.2024 Fehlsichtigkeit Nachrichten

Augentropfen mit niedrig dosiertem Atropin können helfen, das Fortschreiten einer Kurzsichtigkeit bei Kindern zumindest zu verlangsamen, wie die Ergebnisse einer aktuellen Studie mit verschiedenen Dosierungen zeigen.

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

18.04.2024 Spinale Muskelatrophien Nachrichten

Seit 2021 ist die Untersuchung auf spinale Muskelatrophie Teil des Neugeborenen-Screenings in Deutschland. Eine Studie liefert weitere Evidenz für den Nutzen der Maßnahme.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.